Advertisement

Topics

Eisai and Purdue Pharma L.P. Presented Lemborexant Data from Research Studies at ACNP Annual Meeting

08:30 EST 7 Dec 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Additional data published in the Journal of Clinical Sleep Medicine evaluated lemborexant doses for efficacy in insomnia disorder while minimizing residual morning sleepiness Eisai Inc., the U.S. subsidiary of Eisai C...

Other Sources for this Article

Eisai Inc.
Media Inquiries
Laurie Landau, 201-746-2510
laurie_landau@eisai.com
or
Investor Relations Inquiries
Ivor Macleod, 201-746-2660
Senior Vice President, Chief Financial Officer & Chief Compliance Officer
Ivor_Macleod@eisai.com
or
Purdue Pharma L.P.
Danielle Lewis, 203-588-7653
Corporate Communications
Danielle.lewis@pharma.com

NEXT ARTICLE

More From BioPortfolio on "Eisai and Purdue Pharma L.P. Presented Lemborexant Data from Research Studies at ACNP Annual Meeting"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Sleep Disorders
Sleep disorders disrupt sleep during the night, or cause sleepiness during the day, caused by physiological or psychological factors. The common ones include snoring and sleep apnea, insomnia, parasomnias, sleep paralysis, restless legs syndrome, circa...